Growth in prepubertal children with cystic fibrosis, homozygous for the Delta F508 mutation.
METHODS
In cystic fibrosis, growth and lung function have been identified as prognostic markers of both severity of pulmonary disease and survival. Cross-sectional studies in patients with cystic fibrosis (CF) including all genotypes have shown that in prepubertal patients with lifetime continuous care within a specialised CF centre, growth can normalise. No corresponding improvement in lung function has been found. We used a longitudinal design to determine whether normalisation of growth could be found in the genetic subgroup of prepubertal children with CF with the homozygous Delta F508 mutation, which is one of the known severe mutations.


METHODS
Data of all children born after 1980 with the homozygous Delta F508 mutation, diagnosed in early childhood at the specialised centre of the Children's Hospital of Berne were systematically assessed up to the age of 11 years and retrospectively analysed. Follow-up data of height, weight and BMI were compared to the Swiss reference population using z-scores. The correlations between lung function parameters (FEV1, MEF50, VC) and age, as well as lung function parameters and growth indices, were calculated. Additionally, the same correlations were examined in a cohort with the same mutation born 10 years earlier.


RESULTS
In the study, cohort growth (height, weight and BMI) was significantly below that of the normal Swiss population. A significant decline of lung function with age was also found, however, no association between lung function and growth could be seen. Compared to an earlier cohort, an improved growth over the last decade could be shown but no improvement on lung function could be detected. Lung function varied widely in both groups.


CONCLUSIONS
In contrast to sequential cross-sectional studies of children with CF, the present longitudinal study of children with homozygous for the Delta F508 mutation failed to confirm normalisation of growth over time. However, compared to the data of children born in the previous decade, improved growth was observed.
Keller
Bigna M
BM
Department of Pediatrics, University of Bern, 3011 Bern, Switzerland.
Aebischer
Carmen Casaulta
CC
Kraemer
Richard
R
Schöni
Martin H
MH
D000293:Adolescent; D000704:Analysis of Variance; D001827:Body Height; D015992:Body Mass Index; D001835:Body Weight; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000175:diagnosis / Q000235:genetics / Q000401:mortality; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D005260:Female; D005541:Forced Expiratory Volume; D005838:Genotype; D006130:Growth Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D006720:Homozygote; D006776:Hospitals, Pediatric; D006801:Humans; D016014:Linear Models; D008137:Longitudinal Studies; D008297:Male; D008450:Maximal Midexpiratory Flow Rate; D009154:Mutation / Q000235:genetics*; D010446:Peptide Fragments / Q000235:genetics*; D012189:Retrospective Studies; D013557:Switzerland / Q000453:epidemiology; D014797:Vital Capacity
C505032:CFTR protein, human; D010446:Peptide Fragments; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C074197:cystic fibrosis transmembrane conductance regulator (505-511)